Medicines in development in 2009 for brain cancers

[SciMedWeb]

Medicines in development in 2009 for brain cancers:

● 3F8 mAb Phase II
● 8H9 mAb Phase I
● Advexin (contusugene ladenovec) Phase I
● AEE788 Phase I
● AMG 102 Phase II
● ANG-1005 Phase I
● Armala (pazopanib) Phase II
● Avastin (bevacizumab)
● Azedra (iodine-labeled metaiodobenzyl- guanidine) Phase II
● Azixa (MPC-6827) Phase II
● banoxantrone Phase I/II
● berubicin Phase II
● BIBW 2992 Phase I/II
● BMS-844203 (VEGF inhibitor- adnectin) Phase II
● BSI-201 Phase I/II
● CC-8490 Celgene glioblastoma Phase II
● CDX-110 Phase II/III
● cilengitide Phase II
● cintredekin besudotox Phase III
● Cotara (mAb TNT-1) Phase I
● DCVax-Brain Phase II
● EMD 273063 Phase II
● enzastaurin (LY317615) Phase II
● G 207 MediGene glioma Phase I
● gimatecan Phase I/II
● GliAtak (gene therapy) Phase I/II
● ICT-107 (cancer vaccine) Phase I
● Iressa (gefitinib) Phase II
● Karenitecin (cositecan) Phase II
● KRX-0402 Phase II
● laromustine (VNP 40101M) Phase II
● Lucanix (belagenpumatucel-L) Phase I
● lucanthone Phase I
● MLN8237 Phase I/II
● Neuradiab (anti-tenascin mAb 81C6-I-131) Phase III
● OncoGel Phase I/II
● Oncophage (vitespan) Phase II
● panobinostat Phase I/II
● patupilone (EPO906) Phase II
● perifosine Phase II
● PRX-321 Phase II
● Reolysin (reovirus) Phase I/II
● sagopilone Phase II
● SBG Phase I/II
● Systemic hedgehog antagonist Phase I
● talampanel Phase II
● tandutinib (MLN0518) Phase II
● Tarceva (erlotinib) Phase II
● terameprocol Phase I/II
● TheraCIM (nimotuzumab) Phase II
● TM-601 Phase I
● TM-601-I-131 Phase II
● Trisenox (arsenic trioxide) Phase I
● Tykerb (lapatinib) Phase III
● VP101 Phase II
● Xcytrin (motexafin gadolinium)
● Xerecept (corticorelin) Phase III
● XL-184
● XL-765 Phase I
● Zactima® (vandetanib) Phase I
● Zolinza (vorinostat) Phase II

InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)